Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 3/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | KDR | P35968 | 3/20 | 0.63 |
| ▸ | FLT3 | P36888 | 7/20 | 0.60 |
| ▸ | RAF1 | P04049 | 6/20 | 0.59 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.59 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.59 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.59 |
| ▸ | CSF1R | P07333 | 2/20 | 0.58 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13234441 | 0.88 | RAB9A (0.71) | MAPK14MEN1NPC1RAB9AKMT2A | |
| SCHEMBL1698822 | 0.84 | MAPK14 (0.76) | MAPK14MEN1NPC1RAB9AKMT2A | |
| SCHEMBL13234435 | 0.83 | MAPK14 (0.78) | MAPK14MEN1NPC1RAB9AKMT2A | |
| SCHEMBL1255104 | 0.82 | MAPK14 (0.78) | MAPK14MEN1NPC1RAB9AKMT2A | |
| SCHEMBL1698631 | 0.81 | MAPK14 (0.60) | MAPK14MEN1NPC1RAB9AKMT2A | |
| SCHEMBL2951112 | 0.81 | RAB9A (0.77) | MAPK14MEN1NPC1RAB9AKMT2A | |
| SCHEMBL2943933 | 0.80 | MAPK14 (0.78) | MAPK14MEN1NPC1RAB9AKMT2A | |
| SCHEMBL13234666 | 0.80 | MAPK14 (0.78) | MAPK14MEN1NPC1RAB9AKMT2A | |
| SCHEMBL13234418 | 0.80 | MAPK14 (0.78) | MAPK14MEN1NPC1RAB9AKMT2A | |
| SCHEMBL14014125 | 0.80 | KMT2A (0.76) | MAPK14MEN1NPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9296722-B2 | Azolyl urea compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2016-03-29 | — | — | US | disclosed |
| US-20130310357-A1 | Azolyl Urea Compounds and Methods of Use Thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2013-11-21 | — | — | US | disclosed |
| WO-2011150198-A1 | AZOLYL UREA COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2011-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310357-A1 | Azolyl Urea Compounds and Methods of Use Thereof | CSF1R, CSF3R, ARG1 | MAPK14 1010/4885MEN1 2367/4885NPC1 1384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.